by The acute kidney injury treatment market comprises a variety of biologics and pharmaceutical products that are used to treat acute kidney injury caused mainly due to disorders like diabetes, high blood pressure, trauma or drug overdose. During acute kidney injury, the kidneys suddenly lose the ability to filter waste and excess fluid from the blood. Some key products used in the treatment of acute kidney injury include diuretics, renal replacement therapy devices and dialysis consumables. With rising cases of chronic diseases like diabetes and high blood pressure, the global incidence of acute kidney injury has increased substantially over the past decade.
The global acute kidney injury treatment market is estimated to be valued at US$ 1,857.8 million in 2021 and is expected to exhibit a CAGR of 7.2% during the forecast period (2021-2028).
Key Takeaways
Key players operating in the acute kidney injury treatment are Quark Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG., B. Braun Melsungen AG, Fresenius Medical Care, Medtronic, Astellas Pharma Inc., Sentien Biotechnologies, Inc., Teva Pharmaceutical Industries Ltd., Asahi Kasei Medical Co. Quark Pharmaceuticals is developing novel RNA-based treatments for acute kidney injury while Baxter is a leading player for renal replacement therapy devices.
The Acute Kidney Injury Treatment Market Demand prevalence of chronic diseases like diabetes and high blood pressure have substantially increased the risk of acute kidney injury, thereby driving the demand. According to studies, around 13.3 million people suffer from acute kidney injury annually worldwide.
Major players are focusing on expanding their geographical presence with new product launches and regulatory approvals. For instance, in 2020, Quark received approval to conduct phase 3 trial of siRNA therapy in Asia, Europe and other countries to treat acute kidney injury.
Market Key Trends
Rise in incidence of chronic disorders causing organ damage has emerged as a key trend driving the acute kidney injury treatment market. As per studies, chronic diseases account for over 60% of all acute kidney injury cases. Moreover, increasing R&D investments by players and ongoing clinical trials for novel biologics to treat acute kidney injury without requiring dialysis will further fuel the market growth over the forecast period.
Porter’s Analysis
Threat of new entrants: Low capital requirements and established brand recognition create barriers.
Bargaining power of buyers: Large medical facilities and hospitals can negotiate lower prices for acute kidney injury treatment drugs and services.
Bargaining power of suppliers: Suppliers of acute kidney injury treatment raw materials and components face less pressure due to patents held by drug makers.
Threat of new substitutes: Limited substitutes exist for prescription drugs used to treat acute kidney injury. Demand will increase if new therapies prove more effective.
Competitive rivalry: Major drug manufacturers compete on drug efficacy, safety records and marketing. Small biotechs challenge giants with innovative R&D pipelines.
North America accounted for the highest share (~40%) of the acute kidney injury treatment market in 2024 due to major market players presence and increased adoption of therapies in the region. Asia Pacific is expected to grow at the fastest rate during the forecast period with a CAGR of around 9% owing to rising healthcare expenditure, large patient pool and growing access to healthcare facilities.
Geographical Regions
North America was the largest regional market for Acute Kidney Injury Treatment Market Regional Analysis in 2024. This is due to the early approval and adoption of novel drugs in countries like the U.S. and Canada. Presence of leading pharmaceutical manufacturers as well as rising incidence of AKI have also driven market growth.
Asia Pacific is poised to witness the fastest gains during the forecast period from 2024 to 2031. This can be attributed to improving access to healthcare across densely populated nations such as India and China. Rising disposable incomes, growing awareness about AKI, and increasing collaboration between regional players and global industry leaders will further support market expansion.
*Note:
1. Source: Coherent Market Insights, Public Source, Desk Research
2. We have leveraged AI tools to mine information and compile it.
About Author - Money Singh
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc. LinkedIn Profile
